Drug Information

Drug General Information
Drug ID
D0Y1ZU
Former ID
DIB006726
Drug Name
SA-237
Synonyms
Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 3 [524659]
Company
Chugai Pharmaceutical Co Ltd
Target and Pathway
Target(s) Interleukin-6 receptor Target Info Antagonist [544364]
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Non-alcoholic fatty liver disease (NAFLD)
Reactome MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
WikiPathways SIDS Susceptibility Pathways
Senescence and Autophagy in Cancer
IL-6 signaling pathway
Differentiation Pathway
Interleukin-6 signaling
References
Ref 524659ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health.
Ref 544364IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.